JAK inhibitors in systemic juvenile idiopathic arthritis

JAK inhibitors in systemic juvenile idiopathic arthritis

ObjectiveSystemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines. The use of JAKi in SJIA or macrophage activation syndrome (MAS) has only...

Full description

Bibliographic Details
Main Authors: Tingyan He, Yu Xia, Ying Luo, Jun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pediatrics
Subjects:
systemic juvenile idiopathic arthritis
JAK inhibitor
macrophage activation syndrome
tofacitinib
ruxolitinib
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1134312/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1134312/full

Similar Items